Weight-loss drug developer Metsera raises $275 million in US IPO

MBX Biosciences

31/01/2025 24:01

Jan 30 (Reuters) - Weight-loss drug developer Metsera
has raised $275 million after pricing its U.S. initial public
offering at $18 per share, above its targeted range, the ARCH
Venture Partners-backed biotech company said on Thursday.
        

 (Reporting by Prakhar Srivastava and Kanjyik Ghosh in
Bengaluru; Editing by Alan Barona)
 ((Prakhar.srivastava2@thomsonreuters.com))